[Form 4] Affirm Holdings, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Affirm Holdings, Inc. (AFRM) Form 4 summary: On 08/18/2025, Robert O'Hare, CFO, reported transactions effected under a Rule 10b5-1 plan adopted December 6, 2024. The Form 4 shows acquisitions and a subsequent sale: 10,414 shares of Class A common stock were reported acquired at $49 and 991 shares acquired at $57.59, followed by a sale of 11,405 shares at $80, leaving 0 shares of Class A common stock beneficially owned on a non-derivative basis. The filing also discloses stock options: a $49 option covering 10,414 shares and a $57.59 option covering 991 shares; the filing reports 20,829 and 29,071 derivative securities beneficially owned following the transactions, respectively. Vesting schedules and exercise conditions are described in the explanations.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider sold shares under a pre-established 10b5-1 plan; transactions appear structured and routine, not an ad hoc disposition.
The Form 4 shows the CFO executed planned transactions on 08/18/2025 under a 10b5-1 plan adopted 12/06/2024, acquiring interests via option-related exercises at $49 and $57.59 and immediately selling an aggregate 11,405 shares at $80, resulting in zero non-derivative Class A shares held. The filing also documents outstanding stock options and explicit vesting schedules, which clarify future potential dilution and timing of additional option-related activity. For investors, this is notable for transparency on insider liquidity but does not itself indicate a material change to company operations or financial condition.
TL;DR: Transactions follow a documented 10b5-1 plan with detailed vesting terms, consistent with standard insider compliance practices.
The reporting highlights compliance with affirmative defense conditions by citing a 10b5-1 plan adopted 12/06/2024 and provides detailed vesting schedules for two option grants (one with staged annual aggregates and one with 48 monthly installments). The signature by an attorney-in-fact and the explicit explanation of plan-driven sales support procedural conformity. Governance implications are limited: the filing improves disclosure of insider liquidity and option terms but contains no indication of impropriety or governance changes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,414 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 991 | $0.00 | -- |
| Exercise | Class A Common Stock | 10,414 | $49.00 | $510K |
| Exercise | Class A Common Stock | 991 | $57.59 | $57K |
| Sale | Class A Common Stock | 11,405 | $80.00 | $912K |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2024. Stock option vests with respect to 5% of the shares of Class A Common Stock underlying the stock option on the six-month anniversary of January 1, 2021, the vesting commencement date, and the remainder of the grant will vest in quarterly installments over a period of four years, in annual aggregate amounts equal to 15%, 20%, 30% and 30%, respectively, subject to the Reporting Person's continued employment with the Issuer as of each vesting date. The Reporting Person can elect to exercise the stock option at any time, provided that the shares acquired upon exercise remain subject to the applicable vesting schedule. The stock options vest in 48 equal monthly installments beginning December 1, 2024, subject to the Reporting Person's continuous service with the Issuer as of each vesting date.
